Akcea Therapeutics (AKCA) Given Average Rating of “Buy” by Brokerages

Shares of Akcea Therapeutics (NASDAQ:AKCA) have been given a consensus rating of “Buy” by the six analysts that are currently covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $26.67.

Several equities analysts have commented on AKCA shares. BidaskClub lowered shares of Akcea Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, December 30th. Zacks Investment Research upgraded shares of Akcea Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price target on the stock in a research note on Tuesday, January 2nd. Wells Fargo lowered shares of Akcea Therapeutics from an “outperform” rating to a “market perform” rating and set a $27.00 price target on the stock. in a research note on Tuesday, February 27th. Cowen lowered shares of Akcea Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, February 27th. Finally, Stifel Nicolaus lowered shares of Akcea Therapeutics from a “buy” rating to a “hold” rating and set a $20.00 price target on the stock. in a research note on Tuesday, February 27th.

How to Become a New Pot Stock Millionaire

Akcea Therapeutics stock traded down $0.79 during mid-day trading on Monday, hitting $23.18. The company had a trading volume of 133,847 shares, compared to its average volume of 332,410. The firm has a market capitalization of $1,599.28 and a P/E ratio of -10.35. Akcea Therapeutics has a 1 year low of $8.10 and a 1 year high of $33.99.



Akcea Therapeutics (NASDAQ:AKCA) last announced its quarterly earnings results on Monday, February 26th. The company reported ($0.26) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.03). The business had revenue of $18.04 million for the quarter, compared to the consensus estimate of $15.48 million. sell-side analysts predict that Akcea Therapeutics will post -1.32 earnings per share for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in AKCA. Legal & General Group Plc purchased a new position in shares of Akcea Therapeutics during the third quarter worth approximately $111,000. SG Americas Securities LLC purchased a new position in shares of Akcea Therapeutics during the fourth quarter worth approximately $121,000. MetLife Investment Advisors LLC purchased a new position in shares of Akcea Therapeutics during the fourth quarter worth approximately $199,000. Nationwide Fund Advisors purchased a new position in shares of Akcea Therapeutics during the third quarter worth approximately $209,000. Finally, Wells Fargo & Company MN purchased a new position in shares of Akcea Therapeutics during the third quarter worth approximately $222,000. Institutional investors and hedge funds own 29.10% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Akcea Therapeutics (AKCA) Given Average Rating of “Buy” by Brokerages” was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://stocknewstimes.com/2018/04/14/akcea-therapeutics-akca-given-average-rating-of-buy-by-brokerages.html.

About Akcea Therapeutics

Akcea Therapeutics, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. It develops Volanesorsen, which has completed Phase 3 clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase 3 clinical study for the treatment of familial partial lipodystrophy.

Receive News & Ratings for Akcea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply